undamentalytics Newsletter
Sign in

Cencora revenue

Cencora's revenue was $321.33bn in fiscal 2025, up 9.3% on the year before. Since fiscal 2009 ($71.76bn) it has grown at a compound 9.8% a year. Over the last twelve months it was $332.77bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Sept 20092010Sept 20102011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Revenue71.877.878.778.188.0119.6136.0146.8153.1167.9179.6189.9214.0238.6262.2294.0321.3332.8
Growth on the year before—+8.4%+1.2%−0.8%+12.7%+35.9%+13.7%+8.0%+4.3%+9.7%+6.9%+5.7%+12.7%+11.5%+9.9%+12.1%+9.3%—
Gross profit2.12.32.52.62.53.03.54.34.54.65.15.26.98.39.09.911.513.2

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to September 30, 2025
Segments
Line of business Revenue Share YoY
US Healthcare Solutions $291B 90.6% ▲ 9.7%
International Healthcare Solutions $30.4B 9.4% ▲ 6.1%

From Cencora's 10-K filed November 25, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Distributors: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Cencora $332.77bn 5.1% 9.4%
McKesson $410.98bn 8.8% 13.1%
Henry Schein $13.60bn 6.5% 2.6%
111, Inc. $1.75bn -12.7% —
Cosmos Health Inc. $73.7m 33.8% 14.8%
Cellyan Biotechnology Co., Ltd $13.4m -33.9% —

Compare with peers

Head to head: COR vs MCKCOR vs HSICCOR vs YI

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cencora's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cencora.